NCT04214808View on ClinicalTrials.gov

To Evaluate the Pharmacokinetics and Safety of AD-208

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 3, 2020

Primary Completion Date

February 4, 2020

Study Completion Date

May 4, 2020

Conditions
Androgenetic Alopecia
Interventions
DRUG

AD-208

Dutasteride 0.2mg

DRUG

Avodart Soft Capsule 0.5mg

Dutasteride 0.5mg

Trial Locations (1)

41944

Kyungpook National University Hospital, Daegu

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT04214808 - To Evaluate the Pharmacokinetics and Safety of AD-208 | Biotech Hunter | Biotech Hunter